Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder

NCT07046494 is registered in ClinicalTrials.gov with Rapport Therapeutics Inc. as lead sponsor.

NCT NCT07046494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07046494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder
Lead sponsor
Rapport Therapeutics Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 25, 2025
Completion date
October 31, 2026
Enrollment
253 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar 1 disorder